Kelly laments the FDA's latest disappointing decision and extends a personal invitation to celebrate World Diabetes Day with the diaTribe team .

The FDA’s decision on Bydureon was a shocker. We break down this decision and discuss why we view it as such a disappointment.

Medical technology manufacturer Valeritas announced earlier this month that it received FDA clearance to market its V-Go Disposable Insulin Delivery Device, which...

In early November, Kombiglyze, a pill combining DPP-4 inhibitor Onglyza and metformin, was approved by the FDA for type 2 diabetes. Onglyza was approved in July 2010...

In late March, the International Diabetes Federation (IDF) released a "position statement" recommending the consideration of bariatric surgery to treat type 2 diabetes...

On June 16, FDA officials provided an update on its safety review of Takeda’s Actos (pioglitazone), announcing that going forward, prescribing information for Actos will...

According to a recent Apple report , over 425,000 mobile apps are now available in the App Store, with a staggering 200 million users and 15 billion downloads. And...

In June, First Lady Michelle Obama and Walt Disney CEO Robert Iger announced a bold new plan to ban commercials and advertisements for unhealthy food products targeted...

On July 17, the FDA approved Vivus’ weight-loss medication Qsymia (formerly called Qnexa), just several weeks after the approval of Arena’s Belviq (see new now next in...

On November 8, an FDA advisory panel voted 8-4 to recommend approval of Novo Nordisk’s ultra-long-acting basal insulin degludec (to be marketed under the name “Tresiba...

On June 5 and 6, an FDA advisory panel voted in favor of modifying the current Risk Evaluation and Modification Strategy (REMS), for GlaxoSmithKline’s (GSK) Avandia (...

On January 8, the FDA approved Farxiga (dapaglifozin) for the treatment of type 2 diabetes. The drug is called Forxiga in Europe, where it has been approved since...

On November 22, J&J/Janssen Cilags’ SGLT-2 inhibitor Invokana (canagliflozin) was approved in Europe. This makes Invokana the second SGLT-2 inhibitor approved in...

On November 25, the FDA announced the removal of the major restrictions on the prescription and use of GlaxoSmithKline’s Avandia (rosiglitazone) for type 2 diabetes...

On January 7, the FDA announced updated standards for the accuracy of blood glucose monitors for use in both the home and healthcare facility settings. These standards...

On February 27, the FDA published proposed regulations to update nutrition fact labels that would make the familiar labels undergo a dramatic change for the first time...

On April 3, an FDA Advisory Committee voted an overwhelming 13-1 in favor of approving MannKind’s ultra-rapid-acting inhaled insulin Afrezza for type 1 diabetes. The...

On April 16, Vivus announced that the FDA approved a change to the distribution of Qsymia . Qsymia is a weight loss and weight management drug that is designed to be...

Twitter summary: AACE/ACE publish position statement on obesity w/ 4 step plan: screen, examine, evaluate, treat/prevent! Kudos 4 focus on proactive diagnosis The...

Twitter summary: USPSTF releases draft rec. on #T2D screening – defines “at risk” population as 45+, overweight/obese, or 1 st –degree relative w/ #diabetes The United...